ASND ▼ -3.4% - Ascendis Pharma A/S $ASND - First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026 Ascendis Pharma's stock fell 3.4% despite the company presenting first infant data from its TransCon CNP trial at the European Society for Paediatric Endocrinology conference, suggesting the market may have found the efficacy or safety results underwhelming relative to prior expectations. 09-SEP-2026 04:01 PM ET